Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY CAPITAL

26 Jan 2018

Press release / Regulated Information / Transparency Statement 

Leuven, Belgium – Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR) received a transparency notification on 26 January 2018 from Novartis Pharma AG (‘Novartis’).

Novartis notified that, on 26 January 2018, the ThromboGenics shares controlled by Novartis are 2,177,226 shares, or 5.69% of the current 38,271,575 outstanding ThromboGenics shares.

ThromboGenics has issued 2,177,226 new ordinary shares to Novartis, increasing its number of outstanding shares to 38,271,575. This capital increase was approved at the Extra-ordinary Shareholders Meeting of 20 November 2017. 

Novartis subscribed for newly issued shares at a price of €4.593 per share, corresponding with the average of the trading price calculated during the 30 days preceding approval on 20 November 2017.

On 26 January 2018, based on all received transparency declarations received, ThromboGenics NV is aware of the following participations:

 

Shareholder

number of securities

% of voting rights

Mr Thomas M. Clay and entities controlled by him

3,361,555

8.78%

Baron Philippe Vlerick and entities controlled by him

2,324,719

6.07%

Novartis Pharma AG

2,177,226

5.69%

 

 

Press release attachment: 
Tags: 
Investors